查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046061

不可切除的晚期/復發性大腸直腸癌藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、分銷管道、地區和競爭格局分類，2021-2031年

Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球用於治療無法切除的晚期或復發性大腸直腸癌的藥物市場預計將從 2025 年的 35.9 億美元大幅成長至 2031 年的 46.9 億美元，複合年成長率達到 4.56%。

該市場涵蓋多種藥物，例如化療、生物目標製劑和免疫療法，這些藥物專門用於治療已從原發部位轉移到身體其他部位的癌症。該領域的成長主要受全球發病率上升和精準醫療普及的推動。精準醫療利用生物標記檢測來選擇針對每位患者的個人治療方法。對有效治療方法的迫切需求顯而易見，美國癌症協會估計，光是在美國，到2025年就將新增約154,270例大腸癌病例。

市場概覽
預測期 2027-2031
市場規模：2025年 35.9億美元
市場規模：2031年 46.9億美元
複合年成長率：2026-2031年 4.56%
成長最快的細分市場 抗血管內皮生長因子（VEGF）療法
最大的市場 北美洲

然而，創新生物製藥和免疫療法的高昂成本為該市場帶來了巨大的障礙。如此巨大的經濟支出為報銷帶來了嚴峻挑戰，並限制了患者獲得先進治療方案的機會，尤其是在中低收入國家。因此，經濟限制和嚴格的價格管制可能會阻礙高價值療法的廣泛應用，並抑制市場的整體成長。

市場促進因素

全球範圍內不可切除的晚期或復發性結直腸癌發病率的不斷上升是市場成長的主要促進因素，因此，為了應對日益成長的患者群體，進一步的治療性介入至關重要。隨著患者群體（尤其是老年族群）的擴大，對延長生命的藥物治療的需求也隨之增加，從而確保了全身性治療的持續需求。這種發病率的上升與高死亡率密切相關，凸顯了開發有效抗轉移性疾病藥物的迫切臨床需求。美國癌症協會在《2025年癌症事實與數據》報告中預測，到2025年，美國將有約53,000人死於該疾病，這更凸顯了開發先進治療方案的迫切性。這些人口壓力確保了患者的持續湧入，從而鞏固了現有和未來藥物的商業性基礎。

此外，標靶治療和免疫腫瘤藥物的快速湧現正在從根本上改變治療模式，並透過高價生物製藥的引入來提升市場價值。現代臨床方法正從廣譜化療轉向精準醫療，利用VEGF、BRAF和KRAS等生物標記進行個人化治療，以提高病患存活率。這種轉變顯著促進了商業性收入的成長，近期推出的治療機制的快速發展便是明證。例如，HatchMed在其2025年3月發布的「2024年全年業績報告」中指出，標靶治療藥物「Fluzacra」在2024年的市場銷售額達到2.906億美元，這表明新型抑制劑正在迅速發展。為了維持這種創新步伐，產業領導者仍在持續加大投資。例如，根據羅氏公司於 2025 年 1 月發布的“2024 年年度報告”，該公司在 2024 年投資了 130.4 億瑞士法郎用於研發，這凸顯了該行業對癌症治療突破性進展的巨額資金投入。

市場挑戰

創新生物製藥和免疫療法的高昂成本是限制全球不可切除晚期或復發性大腸直腸癌藥物市場成長的主要障礙。儘管這些先進治療方法已證實具有臨床療效，但其高昂的價格卻給醫療預算和全球健保體系帶來了巨大壓力。由於支付方和保險公司為控制成本而實施了嚴格的報銷規則，患者往往面臨獲得維持生命治療的延誤甚至被拒絕的情況。這種情況導致合格的患者群體縮小，直接降低了昂貴療法的普及率，並抑制了製藥公司的潛在利潤。

這種經濟負擔不僅影響保險公司，也影響患者，造成嚴重的經濟困難，並進一步阻礙市場滲透。根據美國癌症協會估計，到2025年，美國癌症患者的相關費用將達到2,11億美元，其中包括大量的自付治療和護理費用。在公共醫療資金往往不足的中低收入國家，這些費用實際上使得病患無法獲得先進的治療。因此，儘管精準醫療在臨床上需求迫切，但維持高價位在經濟上不可行，阻礙了精準醫療更廣泛的商業化和整體市場估值。

市場趨勢

一項重要的市場發展趨勢是針對KRAS G12C突變的特異性抑制劑的商業化，這些抑制劑可用於治療先前被認為無法治癒的患者亞群。這一趨勢包括將阿達格拉西布（adaglasib）和索特拉西布（sotrasib）等藥物引入臨床，這些藥物可抑制致癌性訊號通路，用於治療對標準化療不再有效的不可切除的晚期或復發性結直腸癌患者。這些標靶治療正迅速成為新的標準治療方案，凸顯了治療策略向高度特異性的分子層面介入的轉變。 2024年6月，百時美施貴寶公司發布新聞稿，宣布其KRAZATI獲得美國FDA加速核准。隨後，該公司報告稱， 治療方法在攜帶KRAS G12C突變的結直腸癌患者中取得了34%的客觀緩解率。這凸顯了該領域顯著的臨床療效，並推動了其發展。

同時，腫瘤科醫師擴大將循環腫瘤DNA（ctDNA）液態生物檢體納入治療策略，用於非侵入性分子分析和持續的病患監測。這項診斷技術的進步能夠即時評估微量殘存疾病並快速檢測抗藥性機制，從而避免重複進行有創組織切片檢查，並帶來更精準的治療方法方案。這些以血液為基礎的監測工具正成為精準醫療和追蹤患者療效的關鍵手段，其應用範圍正在迅速擴大。 Natera公司在2024年11月發布的2024年第三季財報中報告稱，其處理了約137,100例腫瘤檢測，年增54%，這表明這些診斷解決方案正在迅速滲透到臨床實踐中。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：不可切除晚期/復發性大腸直腸癌藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（抗 EGFR（表皮生長因子受體）抑制劑、抗 VEGF（血管內皮生長因子）療法、抗 HER2（人類表皮生長因子受體 2）療法、免疫查核點抑制劑、其他）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美不可切除晚期/復發性大腸直腸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲不可切除晚期/復發性大腸直腸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區不可切除晚期/復發性大腸直腸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲不可切除晚期/復發性大腸直腸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲不可切除晚期/復發性大腸直腸癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球不可切除晚期/復發性大腸直腸癌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • Bayer AG
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • AstraZeneca PLC
  • AbbVie Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17561

The global market for metastatic colorectal cancer drugs is projected to expand significantly, rising from USD 3.59 Billion in 2025 to USD 4.69 Billion by 2031, achieving a Compound Annual Growth Rate (CAGR) of 4.56%. This market encompasses various pharmaceutical treatments, such as chemotherapies, targeted biologics, and immunotherapies, specifically developed to manage cancers that have spread from their initial site to other parts of the body. Growth in this sector is largely fueled by the increasing worldwide occurrence of the disease and the growing embrace of precision medicine, which employs biomarker testing to guide tailored therapeutic choices. The pressing need for effective treatments is evident, with the American Cancer Society estimating around 154,270 new colorectal cancer diagnoses in the United States in 2025 alone.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.59 Billion
Market Size 2031USD 4.69 Billion
CAGR 2026-20314.56%
Fastest Growing SegmentAnti-VEGF (Vascular Endothelial Growth Factor) Therapies
Largest MarketNorth America

However, this market faces a notable obstacle stemming from the high expenditures linked to innovative biologic and immunotherapy agents. Such substantial financial outlays pose considerable challenges for reimbursement and restrict patient accessibility to advanced treatment protocols, especially within lower and middle-income nations. As a result, economic limitations and strict pricing regulations are likely to hinder the widespread acceptance of high-value therapeutics and constrain the market's overall financial growth.

Market Driver

The expanding worldwide prevalence of metastatic colorectal cancer serves as a key catalyst for market growth, creating an imperative for more therapeutic interventions to manage the increasing patient population. With an enlarging patient demographic, particularly among older individuals, the demand for life-prolonging pharmacotherapies grows stronger, ensuring a consistent need for systemic treatments. This rising incidence is also linked to a significant mortality rate, emphasizing the urgent clinical necessity for effective drugs against metastatic disease. The American Cancer Society projected approximately 53,000 deaths from this disease in the United States in 2025, according to its 'Cancer Facts & Figures 2025', highlighting the critical need for advanced treatment options. This demographic pressure guarantees a steady flow of patients, thereby solidifying the commercial basis for current and future pharmaceutical products.

Furthermore, the swift emergence of targeted therapies and immuno-oncology agents has profoundly reshaped the treatment paradigm, boosting market value through the integration of high-priced biologics. Contemporary clinical approaches are transitioning from broad-spectrum chemotherapy to precision medicine, where treatments are customized using biomarkers like VEGF, BRAF, and KRAS to enhance patient survival. This shift contributes substantially to commercial revenues, as demonstrated by the quick acceptance of recently introduced mechanisms. For instance, Hutchmed reported in-market sales of the targeted therapy Fruzaqla reaching $290.6 million in 2024, as per their '2024 Full Year Results' in March 2025, showcasing the rapid adoption of novel inhibitors. To maintain this innovative pace, leading industry firms continue to invest heavily; Roche, for example, committed CHF 13.04 billion to research and development in 2024, according to their 'Annual Report 2024' released in January 2025, underlining the sector's significant financial dedication to oncology breakthroughs.

Market Challenge

The substantial cost of innovative biologic and immunotherapy agents presents a significant hurdle to the growth of the global metastatic colorectal cancer drugs market. Although these advanced treatments demonstrate clinical effectiveness, their high prices exert considerable pressure on healthcare budgets and global reimbursement frameworks. With payers and insurance providers implementing strict coverage rules to manage these expenses, patients often face delays or denials in accessing life-prolonging therapies. This situation diminishes the eligible patient pool, directly lowering the adoption rates of expensive therapeutics and curbing the potential revenue for pharmaceutical companies.

Beyond insurers, the financial strain also impacts patients, leading to considerable economic hardship that further curtails market penetration. The American Cancer Society estimated cancer-related costs for patients in the United States at $21.1 billion in 2025, encompassing substantial out-of-pocket expenditures for their treatment and care. In low and middle-income countries, where public health funding is often inadequate, these costs effectively make advanced treatments unattainable. Therefore, despite the clinical necessity for precision medicine, the economic impracticality of sustaining high pricing structures impedes the wider commercialization and overall valuation of the market.

Market Trends

A significant market development is the commercialization of specific inhibitors designed to target the KRAS G12C mutation, addressing a patient subgroup previously deemed untreatable. This trend involves the clinical adoption of agents such as adagrasib and sotorasib, which impede oncogenic signaling in metastatic colorectal cancer patients for whom standard chemotherapy options are no longer effective. These targeted therapies are swiftly becoming a new standard of care, confirming the shift towards highly specific molecular interventions. Bristol Myers Squibb reported in June 2024, following the 'U.S. FDA Accelerated Approval of KRAZATI' press release, that its therapy achieved an objective response rate of 34% in patients with KRAS G12C-mutated colorectal cancer, thereby emphasizing the substantial clinical effectiveness that drives growth in this sector.

Concurrently, oncologists are progressively incorporating circulating tumor DNA (ctDNA) liquid biopsies into treatment strategies for non-invasive molecular profiling and ongoing patient monitoring. This diagnostic advancement facilitates the real-time evaluation of minimal residual disease and the prompt detection of resistance mechanisms, eliminating the necessity for recurrent, invasive tissue biopsies and thereby refining therapeutic choices. The uptake of these blood-based monitoring tools is rapidly increasing as they become vital for guiding precision medicine approaches and tracking patient outcomes. Natera, in its 'Third Quarter 2024 Financial Results' from November 2024, noted processing approximately 137,100 oncology tests, a 54% year-over-year increase, underscoring the swift integration of these diagnostic solutions into clinical practice.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Bayer AG
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • AstraZeneca PLC
  • AbbVie Inc.

Report Scope

In this report, the Global Metastatic Colorectal Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Colorectal Cancer Drugs Market, By Drug Class

  • Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
  • Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
  • Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
  • Immune Checkpoint Inhibitors
  • Others

Metastatic Colorectal Cancer Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Metastatic Colorectal Cancer Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Colorectal Cancer Drugs Market.

Available Customizations:

Global Metastatic Colorectal Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metastatic Colorectal Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors, Anti-VEGF (Vascular Endothelial Growth Factor) Therapies, Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies, Immune Checkpoint Inhibitors, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Metastatic Colorectal Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metastatic Colorectal Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Metastatic Colorectal Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Metastatic Colorectal Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Metastatic Colorectal Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metastatic Colorectal Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Metastatic Colorectal Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Metastatic Colorectal Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Metastatic Colorectal Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Metastatic Colorectal Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Metastatic Colorectal Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metastatic Colorectal Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Metastatic Colorectal Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Metastatic Colorectal Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Metastatic Colorectal Cancer Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Metastatic Colorectal Cancer Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Metastatic Colorectal Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Metastatic Colorectal Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Metastatic Colorectal Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Metastatic Colorectal Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Metastatic Colorectal Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Metastatic Colorectal Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Metastatic Colorectal Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Metastatic Colorectal Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metastatic Colorectal Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. Merck & Co., Inc.
  • 15.4. Pfizer Inc.
  • 15.5. Eli Lilly and Company
  • 15.6. Sanofi S.A.
  • 15.7. Bayer AG
  • 15.8. Amgen Inc.
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Novartis AG
  • 15.11. AstraZeneca PLC
  • 15.12. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer